Edition:
India

Axsome Therapeutics Inc (AXSM.OQ)

AXSM.OQ on NASDAQ Stock Exchange Global Market

3.01USD
14 Dec 2018
Change (% chg)

$-0.06 (-1.95%)
Prev Close
$3.07
Open
$3.01
Day's High
$3.10
Day's Low
$2.96
Volume
44,375
Avg. Vol
38,457
52-wk High
$5.90
52-wk Low
$2.05

Latest Key Developments (Source: Significant Developments)

Axsome Therapeutics Announces Positive Outcome Of Interim Analysis Of AXS-05
Monday, 10 Dec 2018 

Dec 10 (Reuters) - Axsome Therapeutics Inc ::AXSOME THERAPEUTICS ANNOUNCES POSITIVE OUTCOME OF INTERIM ANALYSIS OF ADVANCE-1 PHASE 2/3 TRIAL OF AXS-05 IN ALZHEIMER’S DISEASE AGITATION.AXSOME THERAPEUTICS INC - IDMC RECOMMENDS CONTINUATION OF TRIAL EVALUATING AXS-05 VERSUS PLACEBO IN ALZHEIMER'S DISEASE AGITATION.AXSOME THERAPEUTICS INC - IDMC RECOMMENDS NO FURTHER ENROLLMENT TO SINGLE-AGENT BUPROPION ARM.AXSOME THERAPEUTICS INC - IDMC RECOMMENDS NO FURTHER ENROLLMENT TO SINGLE-AGENT BUPROPION ARM.AXSOME THERAPEUTICS INC - AXSOME INTENDS TO FOLLOW IDMC'S RECOMMENDATIONS..AXSOME THERAPEUTICS INC - IDMC DID NOT INDICATE THAT THERE WERE ANY SAFETY CONCERNS IN STUDY.AXSOME THERAPEUTICS INC - AXS-05 HAS BEEN GRANTED FDA FAST TRACK DESIGNATION FOR TREATMENT OF AD AGITATION.  Full Article

U.S. FDA Says Approved Jazz Pharmaceutical's Narcolepsy Drug, Xyrem, For Pediatric Patients
Saturday, 27 Oct 2018 

Oct 26 (Reuters) - U.S. Food and Drug Administration::U.S. FDA - APPROVED XYREM FOR TREATMENT OF CATAPLEXY AND EXCESSIVE DAYTIME SLEEPINESS IN PEDIATRIC PATIENTS WITH NARCOLEPSY.  Full Article

Axsome Therapeutics Receives FDA Orphan Drug Designation For Axs-12 For The Treatment Of Narcolepsy
Wednesday, 17 Oct 2018 

Oct 17 (Reuters) - Axsome Therapeutics Inc ::AXSOME THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AXS-12 FOR THE TREATMENT OF NARCOLEPSY.AXSOME THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AXS-12 FOR THE TREATMENT OF NARCOLEPSY.AXSOME THERAPEUTICS INC - TOP-LINE RESULTS ANTICIPATED IN FIRST HALF OF 2019.AXSOME THERAPEUTICS INC - PLANS TO INITIATE A PHASE 2 TRIAL OF AXS-12 FOR TREATMENT OF SYMPTOMS OF NARCOLEPSY IN Q4 OF THIS YEAR.  Full Article

Axsome Therapeutics Q2 Loss Per Share $0.32
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - Axsome Therapeutics Inc ::AXSOME THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q2 LOSS PER SHARE $0.32.INTERIM ANALYSIS RESULTS FROM TWO PHASE 3 TRIALS AND TOPLINE RESULTS FROM ONE PHASE 2 TRIAL OF AXS-05 ANTICIPATED IN 4Q 2018.AT JUNE 30, 2018, AXSOME HAD $20.4 MILLION OF CASH COMPARED TO $26.6 MILLION OF CASH AT MARCH 31, 2018.BELIEVES CASH AT JUNE 30, TO BE SUFFICIENT TO FUND ANTICIPATED OPERATIONS INTO Q3 OF 2019.  Full Article

Axsome Therapeutics Appoints Nick Pizzie, Cpa, Mba, As Chief Financial Officer
Thursday, 19 Apr 2018 

April 19 (Reuters) - Axsome Therapeutics Inc ::AXSOME THERAPEUTICS APPOINTS NICK PIZZIE, CPA, MBA, AS CHIEF FINANCIAL OFFICER.AXSOME THERAPEUTICS INC - PIZZIE WILL REPLACE JOHN GOLUBIESKI, CFO, WHO SUBMITTED HIS RESIGNATION ON APRIL 13, 2018.AXSOME THERAPEUTICS INC - PIZZIE WILL REPLACE JOHN GOLUBIESKI, CFO, WHO SUBMITTED HIS RESIGNATION ON APRIL 13, 2018, EFFECTIVE MAY 9, 2018.  Full Article

Axsome Collaborates With A Nicotine Addiction Research Center For Phase 2 Trial Of AXS-05 In Smoking Cessation
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Axsome Therapeutics Inc ::AXSOME THERAPEUTICS COLLABORATES WITH WORLD-LEADING NICOTINE ADDICTION RESEARCH CENTER FOR PHASE 2 TRIAL OF AXS-05 IN SMOKING CESSATION.AXSOME THERAPEUTICS - ‍ENTERED RESEARCH COLLABORATION WITH DUKE UNIVERSITY TO EVALUATE AXS-05 IN A PHASE 2 CLINICAL TRIAL IN SMOKERS ATTEMPTING TO QUIT​.AXSOME THERAPEUTICS INC - ‍PHASE 2 TRIAL INITIATION ANTICIPATED IN Q1 OF 2018 FOR AXS-05​.  Full Article

Sabby Management Reports A 5.52 Percent Passive Stake In Axsome Therapeutics
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Axsome Therapeutics Inc ::SABBY MANAGEMENT, LLC REPORTS A 5.52 PERCENT PASSIVE STAKE IN AXSOME THERAPEUTICS INC AS OF DEC 1 - SEC FILING.  Full Article

Axsome Therapeutics Announces AXS-07 For The Treatment Of Migraine
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Axsome Therapeutics Inc ::AXSOME THERAPEUTICS ANNOUNCES AXS-07 FOR THE TREATMENT OF MIGRAINE.AXSOME THERAPEUTICS INC - ‍PHASE 3 TRIAL ANTICIPATED IN 2018​.AXSOME THERAPEUTICS INC - AXS-07 HAS ‍POTENTIAL FOR "SUPERIOR" EFFICACY AS COMPARED TO CURRENT TREATMENTS​.AXSOME THERAPEUTICS INC - ‍U.S. FDA PRE-INVESTIGATIONAL NEW DRUG APPLICATION​ MEETING WRITTEN GUIDANCE RECEIVED.  Full Article

Axsome Therapeutics reports Q3 loss per share $0.27
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Axsome Therapeutics Inc :Axsome Therapeutics reports third quarter 2017 financial results.Q3 loss per share $0.27.Axsome Therapeutics Inc - ‍Believes its cash as of Sept. 30, 2017 will be sufficient to fund anticipated operations into Q1 of 2019​.  Full Article